FDOPA PET-CT of Nonenhancing Brain Tumors

Bund, Caroline; Heimburger, C.; Impériale, Alessio; Lhermitte, Benoît; Chenard, Marie–Pierre; Lefèbvre, François; Kremer, Stéphane; Proust, F.; Namer, Izzie Jacques

doi:10.1097/rlu.0000000000001540

Cited by 31 publications

(25 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study on brain metastases [ 17 ] and in the present study, a significant [18F] FDOPA uptake (defined by a ratio SUVmax T/S >0.75) in tumours was correlated with a LAT1 score higher than 100, suggesting that, as expected, LAT1 expression may play an important role in [18F] FDOPA uptake and that a minimal LAT1 expression is required for [18F] FDOPA uptake. The lack of direct correlation between the level of LAT1 expression and the level of intensity of [18F] FDOPA uptake in our study may be due to several reasons: sampling and intra-tumour heterogeneity, small size of our series and heterogeneity of tumours (gliomas and metastases), interferences with other factors influencing [18F] FDOPA uptake such as tumour grade [ 22 – 24 ] and treatments [ 20 ].…”

Section: Discussionmentioning

confidence: 80%

[18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression

et al. 2017

View full text Add to dashboard Cite

[18F]-FDOPA is a labeled amino acid (AA) analog used for positron emission tomography (PET) which is gaining increasing interest in the evaluation of brain tumors (BT). The AA-transporter LAT1 has been shown to be involved in [18F]-FDOPA uptake. The aim of this study was to determine whether the [18F]-FDOPA uptake was correlated with level of LAT1 expression in BT. Twenty-eight BT (including 19 gliomas and 9 metastases) were investigated by [18F]-FDOPA-PET prior to surgery and by anti-LAT1 immunohistochemistry on surgical specimens. The quantitative [18F]-FDOPA measured parameters were SUVmax, SUVmean and SUVpeak. LAT1 expression was quantified using a score (0 to 400). A significant [18F]-FDOPA uptake was associated with a LAT1 score ≥ 100 (p = 0.02) but there was no linear correlation between intensity of [18F]-FDOPA uptake and score of LAT1 expression whatever the parameters considered. LAT1 expression alone is not sufficient to explain variation of intensity of [18F]-FDOPA uptake in BT.

show abstract

Section: Discussionmentioning

confidence: 80%

[18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Bund et al analyzed 33 patients with nonenhancing primary brain tumors. An optimal threshold of SUV max T/ N = 2.16 (AUC = 0.87) discriminated low-grade from high-grade gliomas with 60% sensitivity, 100% specificity, 100% PPV, and 83.3% NPV ( p < 0.01) [ 29 ]. Moreover, the authors reported that 18 F-FDOPA was also useful in the subgroup of low-grade gliomas.…”

Section: Resultsmentioning

confidence: 99%

Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature

et al. 2020

Self Cite

View full text Add to dashboard Cite

Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly 18F-FDG PET/CT. In neuro-oncology, 18F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as 18F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of amino-acid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that 18F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed.

show abstract

“…At initial presentation, contrast-enhancement (CE) on the magnetic resonance imaging (MRI) scan, the gold standard for diagnosis and response assessment in malignant gliomas [5], may suggest a high-grade glioma (HGG), and up to 51% of newly-diagnosed GBMs may contain non-enhancing cortical signal abnormality [6]. In a prospective study of 53 newly-diagnosed brain tumor patients with non-CE lesions on MRI, 34% were found to have histologically-proven high-grade glioma [7].…”

Section: Introductionmentioning

confidence: 99%

18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study

et al. 2018

View full text Add to dashboard Cite

show abstract

FDOPA PET-CT of Nonenhancing Brain Tumors

Abstract: Including data from amino acid metabolism used alone or in association with MRSI allows us to discriminate between dysembryoplastic neuroepithelial tumor and grade II oligodendroglioma and between low- and high-grade gliomas with no contrast enhancement on MRI.

Cited by 31 publications

References 29 publications

[18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression

[18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression

Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature

18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study

Contact Info

Product

Resources

About